Rasagaline in ALS
Trial Status
Open for Enrollment
What is the Purpose of this Study?
Rasagiline, approved for treatment
of Parkinson's disease (PD) by the FDA, has broad neuroprotective activities
against a variety of neurotoxins in neuronal cell cultures and in animal
models. Rasagiline has shown delay disease progression and prolong survival
in SOD1 mouse, as well as slowed the ALS patient function deterioration
in a retrospective data analysis from a small group ALS patients.
Who is Eligible to Participate?
Patients diagnosed with Amyotrophic
Lateral Sclerosis who are currently being treated with or without Riluzole,
with no history of liver disease, heart disease or diabetes. Must have
a FVC > than 75%. Can be on low amounts of SSRIs. Patients must also
meet all other inclusion and exclusion criteria explained in further
detail by study coordinator
What is involved in this Study?
This is an open label study. Every patient
will receive 2 mg of Rasagaline and will be treated for about 12 months.
Your first visit is to determine if you are eligible to participate in
the study. This visit consists of a Forced Vital Capacity test to determine
your lung functioning, blood tests, a questionnaire as well as a physical
and nerurological exam. You will receive drug approximately 1week later,
and every 4 weeks you will return to clinic for drug dispensing, blood
tests and neuro exams.
How long is the Study?
It is approximately 50 weeks long.
For More Information Contact: Nicole
C. Hank, MHSM, study coordinator, at 602-258-2432 or nhank@pnal.net or call the Main line at 602-258-3354
